# AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)

Study · id `cardio:ct-nct01118520` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01118520](<https://clinicaltrials.gov/study/NCT01118520>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01118520

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 224 participants.

## Technical summary

Registry record NCT01118520. Randomized; triple masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2015-04 (actual). Results posted on 2021-01-26.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 224 participants (enrolled count; ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Started: 2011-09 (actual) (ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Primary completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Results first posted: 2021-01-26 (ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Countries: United Kingdom (ClinicalTrials.gov record NCT01118520, source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01118520-2021-01-26`, retrieved 2026-11-18)

## The registry's words

- Brief title: AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
- Acronym: AARDVARK
- Condition: Abdominal Aortic Aneurysm
- Intervention (Drug): perindopril arginine
- Intervention (Drug): amlodipine 5mgs
- Intervention (Drug): placebo
- Lead sponsor: Imperial College London
- Lead sponsor class: OTHER
- Collaborator: National Institute for Health Research, United Kingdom
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)
- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: Imperial College London (`cardio:org-imperial-college-london`)
- Registry lists this organization as a collaborator: National Institute for Health Research, United Kingdom (`cardio:org-national-institute-for-health-research-united-kingdom`)

## Provenance

Content hash: ecf11ad52e8751dbe314dca65bf85b00d9ae315b2d727c62a13c1e233ae440a7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
